Citigroup Inc Intercept Pharmaceuticals, Inc. Transaction History

Citigroup Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$9.99 - $18.71 $10.2 Million - $19 Million	-1,017,987 Reduced 87.65%	143,414 $2.66 Million
Q2 2023 Aug 10, 2023	BUY	$9.17 - $19.29 $7.01 Million - $14.7 Million	763,936 Added 192.2%	1,161,401 $12.8 Million
Q1 2023 May 11, 2023	BUY	$12.53 - $21.71 $260,849 - $451,958	20,818 Added 5.53%	397,465 $5.34 Million
Q4 2022 Feb 09, 2023	BUY	$11.61 - $16.11 $693,349 - $962,089	59,720 Added 18.84%	376,647 $4.66 Million
Q3 2022 Nov 10, 2022	BUY	$12.21 - $19.7 $517,984 - $835,733	42,423 Added 15.45%	316,927 $4.42 Million

Q2 2022 Aug 10, 2022	BUY	$11.23 - $19.59 $1.38 Million - $2.4 Million	122,646 Added 80.76%	274,504 $3.79 Million
Q1 2022 May 12, 2022	SELL	$13.37 - $17.79 $2.44 Million - $3.25 Million	-182,833 Reduced 54.63%	151,858 $2.47 Million
Q4 2021 Feb 10, 2022	BUY	$14.28 - $19.53 $1.65 Million - $2.26 Million	115,538 Added 52.72%	334,691 $5.45 Million
Q3 2021 Nov 10, 2021	BUY	$12.99 - $20.47 $2.85 Million - $4.49 Million	219,153 New	219,153 $3.25 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.